Slide 1: Q2 2025 Earnings Presentation
Q2 2025 Earnings Presentation August 6, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance, including its outlook
Slide 3: Q2 2025 Revenue
Q2 2025 Revenue1 Product Revenue Service Revenue $57.5 Commentary (Y/Y) $51.5 $46.6 $45.6 • Total revenue declined 2% Y/Y $41.5 • Driven by lower EMEA & APAC $45.0 product revenue2 $39.5 $34.6 $31.4 $28.1 • Offset by strong growth in service and reagent revenue, which each grew 18%, as well as growt
Slide 4: Recurring Revenue Businesses Continue to Grow Steadily
Recurring Revenue Businesses Continue to Grow Steadily1 27% of TTM Total 32% of TTM Total Revenue Revenue $143.4M $133.3M 16% Y/Y Growth Other Revenue2 $54.3M $62.8M Service + Reagent Revenue As of Q2 2024 As of Q2 2025 1. Recurring revenue is comprised of service and reagent revenue 2. Other revenu
Slide 5: FSP Instrument Placements
FSP® Instrument Placements1 Total FSP Units Sold Commentary (Y/Y) 164 • 3% growth in FSP unit volumes 138 • Led by Cytek Aurora Analyzer 110 113 • US FSP unit volumes were up 10% 88 versus Q1 2025 • Demonstrates strength of core business • FSP instruments: essential to customer workflows Q2 2024 Q3
Slide 6: Revenue by Geographic Region
Revenue by Geographic Region1 Commentary (Y/Y) $57.5 • US: Revenue up 7% driven by growth in $51.5 pharma/biotech and service, offset by $46.6 $45.6 academic/government $41.5 • EMEA: Revenue declined 11% driven by weakness in pharma/biotech, partially offset by academic/government and service • APAC
Slide 7: Solidifying our Leadership in the Spectral Flow Cytometry Market
Solidifying our Leadership in the Spectral Flow Cytometry Market Northern Lights Analyzer Introducing Cytek Aurora Evo Analyzer: the latest advancement in spectral flow cytometry Cytek Aurora Analyzer Faster sample throughput Automated instrument start up and shutdown Cytek Aurora Cell Sorter Enhanc
Slide 8: Strong Execution Across Growth Pillars Q2 2025
Strong Execution Across Growth Pillars Q2 2025 Instruments Bioinformatics Applications Clinical Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in Q2 of 2025, and representing 3% unit growth of Cytek FSP instruments compared to Q2 of 2024 Launched Cytek Aurora Evo sys
Slide 9: Q2 2025 Financial Overview
Q2 2025 Financial Overview in millions Q2 2025 Q2 2024 Y/Y Total Revenue $45.6 $46.6 (2)% Product $31.4 $34.6 (9)% Service $14.2 $12.0 18% Gross Profit $23.9 $25.4 (6)% Gross Margin 52% 55% (5)% Operating Expenses $34.5 $34.0 2% Loss from Operations ($10.6) ($8.5) (20)% Net Loss ($5.6) ($10.4) 46% N
Slide 10: Full Year 2025 Revenue Guidance
Full Year 2025 Revenue Guidance FY 2025 Revenue1 $196 - $205 -2 to +2% y/y growth 1. Assumes no change from current currency exchange rates 10
Slide 11: Well-positioned for Growth and Profitability
Well-positioned for Growth and Profitability Technology Platform Leader Strengthening market leadership through innovation that redefines industry standards, accelerates adoption and creates new markets Global Diversification Multiple geographies and service and product revenue streams Growing Recur
Slide 12: Appendix
“CYTE K* TRANSCEND THE CONVENTIONAL. Appendix
Slide 13: Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Measures (Unaudited) Three months ended (In thousands) June 30, 2025 June 30, 2024 (Unaudited) (Unaudited) GAAP Gross profit $ 23,867 $ 25,436 Stock based compensation $ 1,110 $ 1,200 Amortization of acquisition-related intangible assets $ 481 $ 503 Non-GAAP Adjust
Slide 14: Thank You
e - TRANSCEND THE CONVENTIONAL ‘Thank You